Calon Cardio-Technology
Calon Cardio-Technology was a Swansea-based medtech firm developing next-generation implantable micro-pumps for heart failure treatment; it entered administration in 2026 and was being liquidated with a £5.4m deficit to creditors.
- Company typePrivate
- Founded2007
- HeadquartersSwansea, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Calon Cardio-Technology does
Calon Cardio-Technology was a Swansea, Wales-based medical device company developing next-generation implantable micro-pumps intended for the treatment of heart failure. Founded in 2007 (per firmographics) and operating with a small team in the 11-50 headcount band, the company targeted the cardiac assist device market, which third-party sources projected to reach $3.76 billion by 2030 at a 10.4% CAGR. Its core product was an implantable micro-pump designed to support cardiac function in heart failure patients, and the company was led by founder Stephen Westaby, a recognized figure in cardiac surgery and mechanical circulatory support research. The technology description in available sources covers cardiac assist device mechanics only; no AI, software platform, or digital health components are disclosed.
Calon's business model was that of an R&D-stage, pre-revenue medtech: the company developed its pump technology with a view to eventual regulatory approval and commercialization rather than current-period sales. It raised approximately £3.5m in disclosed equity and debt funding, primarily from the Development Bank of Wales (which held a 9% stake at administration) and its predecessor Finance Wales, with additional capital from Longbow Capital and a 2015 SyndicateRoom-led round of approximately $1.9m. No commercial products, pricing models, customer relationships, or recurring revenue streams are disclosed in the available data, consistent with a pre-commercial development posture.
In mid-2026, after a proposed £39m acquisition by AIM-listed Ashington Innovation collapsed and a planned $2.6m funding injection from a US-based lender failed to clear UK Anti-Money Laundering compliance checks, Calon entered administration. By February 2027 the company was being liquidated with a £5.4m deficit to creditors including HMRC, Swansea Council and Swansea University. 17 former employees were owed wages and holiday pay as preferential creditors, and no buyer or company voluntary arrangement emerged to continue the business; the operating status is recorded as closed.
Calon Cardio-Technology firmographics
Firmographics- Name
- Calon Cardio-Technology
- Legal name
- Calon Cardio-Technology
- Website
- https://caloncardio.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Closed
- Headcount range
- 11–50 employees
- Short description
- Calon Cardio-Technology was a Swansea-based medtech firm developing next-generation implantable micro-pumps for heart failure treatment; it entered administration in 2026 and was being liquidated with a £5.4m deficit to creditors.
- Ownership category
- akta.pro rank
Calon Cardio-Technology industry classification
Industry- Product category
- Cardiac Assist Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)
- akta.pro secondary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
Keywords
Where Calon Cardio-Technology is headquartered
LocationHeadquarters
- HQ city
- Swansea
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Calon Cardio-Technology business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Calon Cardio-Technology product offering
Product offeringCore offering
Calon Cardio-Technology is developing a next-generation implantable micro-pump intended for the treatment of heart failure. The company operated as a Swansea-based medtech firm focused on cardiac assist device technology for the cardiovascular/heart failure treatment market.
Differentiator
Problem solved
Functional benefit
Products and services
- Implantable Micro-Pump for Heart Failure
Companies that use Calon Cardio-Technology
Customer profileIdeal customer profiles1 record
Calon Cardio-Technology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Calon Cardio-Technology partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights2 records
Calon Cardio-Technology competitors and assessment
Company assessmentEmerging players
- Magenta Medical: Builds the world's smallest heart pump (Elevate) for circulatory support; a venture-stage peer pursuing miniaturized cardiac assist technology.
- BiVACOR: Developing a rotary total artificial heart using maglev pump technology; an emerging mechanical circulatory support peer for end-stage heart failure.
- FineHeart: European company developing an implantable flow maker (ICOMS) for heart failure; comparable emerging implantable cardiac assist developer.
- CorWave: French startup developing a novel implantable LVAD with a wave-membrane pump; a close emerging-stage analogue pursuing next-generation implantable heart pumps like Calon.
- Evaheart: Develops an implantable centrifugal LVAD for advanced heart failure; a niche peer in the implantable cardiac pump segment Calon pursued.
- CARMAT: Maker of the Aeson total artificial heart for advanced heart failure; a comparable European implantable cardiac device company addressing the same end-stage patient population.
- Procyrion (Aortix): Developing a catheter-deployed intra-aortic micro-pump for heart failure, directly comparable to Calon's micro-pump approach for circulatory support.
Broad incumbents
- Abiomed: Maker of the Impella percutaneous heart pump and a leader in mechanical circulatory support; directly relevant as the dominant player in the cardiac assist pump category Calon targeted.
- Abbott (HeartMate): HeartMate LVAD is the market-leading implantable ventricular assist device for heart failure, the exact device class Calon's micro-pump aimed to compete in.
Regional players
- Berlin Heart: European manufacturer of ventricular assist devices (EXCOR, INCOR) for heart failure; a comparable circulatory support device maker primarily serving European markets.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat2 records
Key highlights5 records
Customer concentration
Calon Cardio-Technology social profiles
Digital presenceCalon Cardio-Technology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Calon Cardio-Technology leadership team
Management profileNumber of profiles
Profiles1 record
Calon Cardio-Technology funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Calon Cardio-Technology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Calon Cardio-Technology
What does Calon Cardio-Technology do?
Calon Cardio-Technology is developing a next-generation implantable micro-pump intended for the treatment of heart failure. The company operated as a Swansea-based medtech firm focused on cardiac assist device technology for the cardiovascular/heart failure treatment market.
Is Calon Cardio-Technology a public or private company?
Calon Cardio-Technology is a private company. It is classified as venture growth investor backed and is currently closed.
When was Calon Cardio-Technology founded?
Calon Cardio-Technology was founded in 2007. It employs 11 to 50 people.
Where is Calon Cardio-Technology based?
Calon Cardio-Technology is headquartered in Swansea, United Kingdom, in the Europe region.
Who are Calon Cardio-Technology's main competitors?
Emerging players on record are Magenta Medical, BiVACOR, FineHeart, CorWave, Evaheart, CARMAT and Procyrion (Aortix). Broad incumbents are Abiomed and Abbott (HeartMate). Berlin Heart is listed as a regional player.
Does Calon Cardio-Technology have an API?
No public API is recorded for Calon Cardio-Technology.
What industry is Calon Cardio-Technology in?
Calon Cardio-Technology's product category is Cardiac Assist Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.